Authors: Francesco Burzotta Marta Francesca Brancati Carlo Trani Giancarlo Pirozzolo Gianluigi De Maria Antonio Maria Leone Giampaolo Niccoli Italo Porto Francesco Prati Filippo Crea
Publish Date: 2015/04/12
Volume: 31, Issue: 5, Pages: 677-686
Abstract
The efficacy of DEB in modifying the high restenosis risk associated with BMS implantation is doubtful Optical coherence tomography OCT may allow precise assessment of neointimal formation after stent implantation We performed a singlecenter prospective 12 randomized trial comparing BMS implantation alone BMS group vs additional DEB DEB group DEB patients were further randomized 11 to DEB before stenting preDEB group or after stenting postDEB group Primary endpoint was OCTassessed neointimal hyperplasia expressed both as mean instent neointimal area and as percentage obstruction of the mean stent area at 6 months Secondary endpoints were the percentage of uncovered and malapposed stent struts Thirty patients were enrolled and randomized to BMS n = 10 preDEB n = 10 postDEB n = 10 At 6month OCT followup DEB significantly reduced neointimal area compared with BMS mean neointimal area 201 ± 089 vs 303 ± 107 mm2 p = 002 percentage area obstruction 2456 ± 1250 vs 3751 ± 1226 p = 002 The percentage of uncovered and malapposed stent struts did not differ significantly between BMS and DEB In the comparison between preDEB and postDEB no significant difference was observed for both primary and secondary endpoints In de novo coronary lesions treated with BMS DEB use could be associated with a mild reduction in neointimal hyperplasia at 6 months this effect could be unrelated to the timing of DEB dilation pre or poststenting
Keywords: